Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Publication | Open Access

DOI Full Paper Access

204

Citations

References

2006

Year

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí, A. Ruíz, Manuel Ramos, Encarna Adrover, Álvaro Rodríguez-Lescure, Lourdes Calvo, Concepción Fernández‐Chacón, Montserrat Roset,

Annals of Oncology

Breast OncologyBreast Cancer PatientsMedicineHealth-related QualityTac RegimenPharmacologyCancer ManagementBreast CancerPharmacotherapyCancer TreatmentOncology